1 not yet recruiting, 1 recruiting. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow JBI-778: new trials by email Literature Review of JBI-778 trials Research Report on JBI-778
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma JBI-778 - Brain Metastases From Solid Tumors, Leptomeningeal Disease | Phase 1 / Phase 2 | Not yet recruiting | Jubilant Therapeutics Inc. | 113 | 2028-04-01 | 2026-08-07 |
| First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety Drug-level in Blood & Drug Metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients With, Without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary Glands Tumor JBI-778 - NSCLC Patients With EGFR Activating Mutation, Adenoid Cystic Carcinoma Metastatic | Phase 1 | Recruiting | Jubilant Therapeutics India Limited | 30 | 2024-08-26 | 2026-08-10 |
Brain Neoplasms (1) · Glioblastoma (1) · Glioma (1) · Meningeal Neoplasms (1)
Jubilant Therapeutics Inc. (1) · Jubilant Therapeutics India Limited (1)
India (1)